daunorubicin has been researched along with altretamine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cox, PJ; Farmer, PB | 1 |
| Kerstjens, HA; Lo, GT; Meinesz, AF; Postmus, PE; Sleijfer, DT; Sluiter, HJ | 1 |
| Carter, SK | 1 |
3 review(s) available for daunorubicin and altretamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Towards selectivity? Approaches to the design of new anti-tumour agents--II.
Topics: Altretamine; Amino Acids; Antineoplastic Agents; Carbohydrates; Chelating Agents; Colchicine; Coloring Agents; Dacarbazine; Daunorubicin; Doxorubicin; Drug Interactions; Ellipticines; Folic Acid Antagonists; Heart Diseases; Humans; Lectins; Neoplasms; Nitrosourea Compounds; Peptide Hydrolases; Podophyllotoxin; Polymers; Structure-Activity Relationship | 1977 |
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Female; Gallium; Humans; Ifosfamide; Leukemia; Vinblastine; Vindesine; Zinostatin | 1980 |
1 trial(s) available for daunorubicin and altretamine
| Article | Year |
|---|---|
New cytotoxic drugs for breast cancer and their clinical evaluation.
Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Daunorubicin; Doxorubicin; Female; Gallium; Humans; Ifosfamide; Leukemia; Vinblastine; Vindesine; Zinostatin | 1980 |
4 other study(ies) available for daunorubicin and altretamine
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
No response improvement after sequential chemotherapy for small cell lung cancer.
Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cyclophosphamide; Daunorubicin; Drug Evaluation; Etoposide; Female; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged; Prednisone; Time Factors; Vincristine | 1986 |